Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein by Gregson, Aric L. et al.
Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B
Core Virus-Like Particle Containing Epitopes of
Plasmodium falciparum Circumsporozoite Protein
Aric L. Gregson
1¤a, Giane Oliveira
2¤b, Caroline Othoro
2, J. Mauricio Calvo-Calle
2¤c, George B. Thorton
3,
Elizabeth Nardin
2, Robert Edelman
1*
1Department of Medicine and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 2Department
of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America, 3Apovia, Inc., San Diego, California, United
States of America
Abstract
The objectives of this non-randomized, non-blinded, dose-escalating Phase I clinical trial were to assess the safety,
reactogenicity and immunogenicity of ICC-1132 formulated with Alhydrogel (aluminum hydroxide) in 51 healthy, malaria-
naive adults aged 18 to 45 years. ICC-1132 (Malariavax) is a recombinant, virus-like particle malaria vaccine comprised of
hepatitis core antigen engineered to express the central repeat regions from Plasmodium falciparum circumsporozoite
protein containing an immunodominant B [(NANP)3] epitope, an HLA-restricted CD4 (NANPNVDPNANP) epitope and a
universal T cell epitope (T*) (amino acids 326—345, NF54 isolate). We assessed an Alhydrogel (aluminum hydroxide)-
adjuvanted vaccine formulation at three ICC-1132 dose levels, each injected intramuscularly (1.0 mL) on study days 0, 56
and 168. A saline vaccine formulation was found to be unstable after prolonged storage and this formulation was
subsequently removed from the study. Thirty-two volunteers were followed for one year. Local and systemic adverse clinical
events were measured and immune responses to P. falciparum and hepatitis B virus core antigens were determined utilizing
the following assays: IgG and IgM ELISA, indirect immunofluorescence against P. falciparum sporozoites, circumsporozoite
precipitin (CSP) and transgenic sporozoite neutralization assays. Cellular responses were measured by proliferation and IL-2
assays. Local and systemic reactions were similarly mild and well tolerated between dose cohorts. Depending on the ICC-
1132 vaccine concentration, 95 to 100% of volunteers developed antibody responses to the ICC-1132 immunogen and HBc
after two injections; however, only 29—75% and 29—63% of volunteers, respectively, developed malaria-specific responses
measured by the malaria repeat synthetic peptide ELISA and IFA; 2 of 8 volunteers had positive reactions in the CSP assay.
Maximal transgenic sporozoite neutralization assay inhibition was 54%. Forty-seven to seventy-five percent demonstrated T
cell proliferation in response to ICC-1132 or to recombinant circumsporozoite protein (rCS) NF-54 isolate. This candidate
malaria vaccine was well tolerated, but the vaccine formulation was poorly immunogenic. The vaccine may benefit from a
more powerful adjuvant to improve immunogenicity.
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Introduction
An effective vaccine is needed to prevent or attenuate disease
from Plasmodium falciparum malaria, the most important cause of
malaria morbidity and mortality throughout the world [1].
Protection from P. falciparum malaria infection and challenge was
first demonstrated following immunization of humans with
irradiation-attenuated P. falciparum sporozoites [2]. High levels of
antibody directed against repeat regions of the circumsporozoite
protein (CS) and high levels of interferon (IFN)-c production by
CD4
+ and CD8
+ cells against epitopes of CS, is associated with
protection of humans and primates from P. falciparum malaria [3–
7]. These findings suggest that a subunit vaccine which elicits
robust humoral immunity directed against the extracellular
sporozoite and robust cellular immunity with which to eliminate
infected hepatocytes, could prevent patent blood-stage infection,
the stage of the infection responsible for clinical illness.
Virus-like particles have been used recently as highly immuno-
genic delivery platforms for a variety of vaccines [8–13]. The virus-
like particle malaria vaccine RTS,S is composed of hepatitis B virus
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(aminoacids207—395)oftheP.falciparumNF54isolate(3D7 clone).
In combination with potent proprietary adjuvants, this vaccine has
protective efficacy against malarial disease and severe malaria [14–
17]. Complete protection was obtained in 40% of immunized
malaria naive volunteers undergoing sporozoite challenge [15,18]
and 30% protection against the first clinical episode of malaria for
18 months in children living in malaria endemic areas [16,17].
More robust vaccines capable of greater and longer duration of
protection are sought through more effective vaccine delivery
platforms. The hepatitis B virus core protein (HBc) has been
demonstrated to be an effective malaria vaccine platform in animals
where high levels of anti-CS repeat antibodies protected animals
from malaria challenge [19,20].
Circumsporozoite protein is comprised of a central portion of
amino acid repeats (NANP) representing dominant T cell-
dependent B cell epitopes [21,22]. T cell epitopes have been
identified in the CS molecule, which are HLA-restricted CD8
+
and CD4
+ T cell epitopes, as well as universal CD4
+ T cell
epitopes [6,23–25]. The present vaccine, ICC-1132, was con-
ceived in an effort to boost antibody levels and generate a robust
cellular immune response. It is comprised of central repeat regions
of CS containing (1) both immunodominant B (NANP)3 and HLA-
restricted CD4
+ T cell (NANPNVDP) epitopes identified from
irradiated sporozoite immunization studies [5,21], (2) a universal
T cell epitope (T*) from the carboxyl terminus of CS (amino acids
326—345 NF54 isolate) containing CD4
+ T cell epitopes, which
bind to a wide range of HLA types [24,26,27], and (3) at least one
CD8
+ T cell epitope [28]. These CS epitopes are inserted into a
HBc backbone which spontaneously aggregates to form virus-like
particles. This vaccine was found to be highly immunogenic in
rodent and non-human primates [29].
After initiation of this present study in the USA, the ICC-1132
vaccine was tested in other, more limited studies in Europe, the
results of which have been published [30–32]. A study in Cardiff,
Wales used the same protocol as the present study, but included only
the 20 and 50 mcg vaccine doses with the same Alhydrogel adjuvant
[30]. A limited analysis of cellular immune responses was carried out
using IFN-c ELISpot. Immunogenicity of a single injection of ICC-
1132 formulated with Seppic ISA 720 adjuvant, instead of
Alhydrogel, was assessed in a Phase 1 dose response study [32]
andinaPhase1/2trialofasingledoseof50mcg/ISA720[31].The
present study was initially designed to be a phase 1/2 study of the
three ICC-1132 concentrations in either saline or adsorbed to
Alhydrogel, followed by a malaria challenge trial. Because the
malaria challenge was not performed, this report summarizes the
results of the phase 1 trial of ICC-1132 in the United States.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
The trial took place on the campuses of the University of
Maryland at Baltimore and at College Park. The study methods
and rationale, along with the study consent was explained to
potential healthy, adult participants aged 18—45. A written exam
was administered to potential participants to assess their
understanding of the study procedures, rationale and expected
outcomes. Consented participants were screened by medical
history, physical examination and laboratory analysis of hemato-
logic and serologic markers. Exclusion criteria included medical
history or serologic indications of malaria, HIV, HBsAg or any
significant cardiovascular, hepatic or renal function abnormalities.
Interventions
Vaccine Construct. The vaccine has been described [29]. In
summary, recombinant ICC-1132 is comprised of the assembly
domain of the HBc gene (amino acid residues 1—149) with the CS
universal T cell epitope (T*) (CS amino acid residues 326—345)
fused to the HBc C-terminus following Val149 [33] (Figure 1). The
B and T cell CS repeat epitopes, T1 (NANPNVDPNANP) and B
[(NANP)3], are inserted into the HBc immunodominant loop
between amino acid residues Asp78 and Pro79. Recombinant HBc
dimers self-assemble into an icosahedral virus-like particle of
approximately 30 nm in diameter composed of 180—240
individual copies of the recombinant protein [29,33]. Based on
HBc structure, the CS repeats contained in ICC-1132, inserted
between amino acid residues 78 and 82 of HBc, are believed to be
localized to the tip of surface spikes on the particle formed by
dimerization of HBc monomers [33,34]. The T* epitope replaces
the HBc protamine-like domain (HBc amino acid residues 150—
183) and is therefore most likely oriented to the inner surface of the
core particle, which is believed to be similar to its orientation in the
native circumsporozoite protein.
ICC-1132 was adsorbed to aluminum hydroxide (Alhydrogel;
Superfos, Frederikssund, Denmark) with .95% adsorption as
determined by measurement of residual unbound protein. Each
1 mL of vaccine contained 1 mg of aluminum as Al(OH)3. The
saline formulation contained the same concentration of ICC-1132,
Figure 1. The T1(B)3 repeat epitopes, NANPDVDP(NANP)3, are
inserted between amino acid residues 78 and 82 of the
hepatitis B core protein, forming the tip of the core antigen
spikes. The T* epitope, EYLNKIQNSLSTEWSPCSVT, is inserted starting at
amino acid V149. The amino terminus is noted as H2N and the starting
amino acid is labelled as M1. Adapted from Bottcher, et al.
doi:10.1371/journal.pone.0001556.g001
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purified and formulated by Apovia, Inc.
Study Design. The study was originally designed as a double-
masked, dose-escalating trial comparing the three dose levels (10,
20 and 50 mcg) of ICC-1132 in saline to the same three dose levels
of ICC-1132 adsorbed to Alhydrogel. In January 2003 the trial
was delayed because the saline formulation of the vaccine was
found to be unstable after six to nine months’ storage at 4uC. The
saline formulation was subsequently removed from the study,
leaving the stable alum preparation to be tested. The study was
redesigned to assess the 20 and 50 mcg doses of the Alhydrogel
vaccine in a non-masked, dose escalating fashion. The study was
conducted according to GCP guidelines. Ethical approval for the
study was obtained from the Institutional Review Boards of the
University of Maryland, Baltimore and University of Maryland,
College Park and the New York University School of Medicine.
Objectives
The primary objectives were (1) to compare the safety and
reactogenicity of ICC-1132 in saline and with the Alhydrogel
formulation in healthy, malaria-naive human adults, and (2) to
assess the immunogenicity of the two ICC-1132 vaccine
formulations. A secondary objective was to vaccinate a sufficient
number of volunteers who would agree to participate in a
concurrent malaria challenge trial. The immunogenicity data for
the saline formulation is abbreviated for reasons described. The
malaria challenge trial was cancelled because of lack of sufficient
immunogenicity, predefined as a dose cohort median IFA of
$1500.
Outcomes
Safety and Reactogenicity. Local and systemic reactions
were assessed for 30 minutes following each injection. Clinical
assessments were carried out at 1, 2, 7, 14, 28 and 56 days after
each injection, at day 84 after the second injection, and day 168
after the third injection. Telephone interviews were conducted at
4 days after each injection and volunteers maintained a daily diary
to collect adverse events and twice daily body temperature
recordings in the seven days immediately after each injection.
Local Reactions. Tenderness, pain, erythema, induration
and pruritus, at the site of injection, were graded.
Systemic Reactions. Solicited systemic variables evaluated
included fever, chills, malaise, headache, photophobia, anorexia,
nausea, vomiting, abdominal pain, myalgia, arthralgia and rash.
Non-solicited adverse event reported by a volunteer was recorded
and an assessment of causality was performed by the investigators.
Local and Systemic Events Grading. Local and systemic
adverse events were graded according to the following schema:
Grade 1 mild, no change in activity and/or no medication
necessary; Grade 2 moderate, requires change in activity and/or
medication; Grade 3 severe, bed rest required/inability to perform
normal activities and/or medical intervention other than
medication alone (such as an outpatient visit in emergency
department or clinic, excluding hospitalization).
Clinical Chemistry. Urinalysis, hematological and
biochemical safety analysis was carried out prior to vaccine
injections, 2, 14, 28 days after all injections, 84 days after the
second injection, and 56 and 168 days after the third injection.
Immunogenicity – Serologic Assays. Serum samples for
serological assays and peripheral blood mononuclear cells (PBMC)
for cellular immune assays were obtained at the time of each
immunization, 14 and 28 days after each injection, 84 days after the
second injection, and 56 and 168 days after the third injection.
Methods used for ELISA, IFA and CSP reactions are identical to
those previously published [30]. Significant values were taken to be a
$4-fold increase from baseline titers. Antibody reactivity with viable
sporozoites was assessed by circumsporozoite precipitin (CSP)
reaction in which antibody mediated cross linking of surface CS
protein results in formation of a terminal precipitin reaction on
sporozoites detectable by phase microscopy [35]. The presence of
neutralizing antibodies in immune sera was determined using a
Transgenic Sporozoite Neutralization Assay (TSNA) based on
transgenic rodent Plasmodium berghei sporozoites expressing P.
falciparum CS repeats [36,37]. In the TSNA, 2x10
4 transgenic
sporozoites were incubated in serum (1:5 dilution) from each
volunteer or with controls of medium only or 25 mcg/mL of either
mAb 3D11, specific for P. berghei repeats, or mAb 2A10, specific for
P.falciparumrepeats.Sporozoiteswereincubatedwithserum,mAbor
medium for 40 minutes on ice prior to their being added to human
hepatoma cell (HepG2) cultures. The cultures were incubated for
72 hours followed by extraction of total RNA from the cells for
determination of intracellular parasites by RT-PCR using primers
specific for parasite 18S ribosomal RNA. All TSNA were performed
in duplicate. Inhibition of .85% is considered positive.
Immunogenicity – Cellular Assays. The PBMC were
Ficoll purified from blood collected in citrate buffer Vacutainer
(BD Biosciences, San Diego, CA). Short term TCL were used in
the assays by expanding PBMC (2x10
6/mL) with a single in vitro
stimulation with rCS (10 mcg/mL) with recombinant human
interleukin-2 (IL-2) added on day five [32,38]. In the proliferation
assay, the short term TCL were incubated in triplicate wells with
various concentrations of rCS or HBc proteins or peptides
representing the CS repeats (T1B)4 or the universal T cell
epitope (T*). Culture wells tritiated with
3H-Tdr on day five were
incubated overnight and harvested. The results are expressed as
delta (d) cpm (cpm in cultures stimulated with antigen – cpm in
cultures without antigen) or stimulation index (SI) (cpm in antigen
stimulated cultures/cpm induced by supernatants from medium
only cultures). IL-2 was measured in a bioassay using 24 hour cell
culture supernatants incubated with an IL-2 dependent cell line
[32,38] and the results expressed as d cpm or SI. Significant
responses were taken as d cpm.mean+2 standard deviations of
responses obtained with pre-immune cells from the volunteers.
Sample size
In this phase 1 descriptive study focusing on safety and
immunogenicity, sample sizes were derived from logistic consid-
erations, rather than by power analyses. The larger number of
volunteers in the 50 mcg cohort was designed to yield sufficient
interested volunteers to enable a malaria challenge trial after the
third vaccination.
Randomization—Sequence generation
Using SAS, a randomization list was prepared in advance of
vaccination activities with randomized block of N=2 (one subject
receiving saline and the other Alhydrogel formulated vaccine) for
the August 2002 cohorts.
Randomization—Allocation concealment
Assignments to vaccine groups from this randomization were
placed in individual sealed envelopes and were provided to the
immunization team. Randomization assignment was masked from
investigators assessing post-injection adverse events.
Randomization—Implementation
The original study statistician generated the allocation
sequence. Subjects in the 10 mcg cohort and the first three
ICC-1132 Alum USA Phase1 Trial
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receive ICC-1132 in saline or ICC-1132 adsorbed to Alhydrogel.
All 32 subsequent subjects received ICC-1132 adsorbed to
Alhydrogel, and were allocation to either the 20 mcg or 50 mcg
cohorts on a first come, first serve basis, such that the first eight
available subjects were assigned the 20 mcg cohort, while the last
24 subjects were assigned the 50 mcg cohort.
Blinding
The participants, vaccine administrators and clinical staff
providing safety follow-up were blinded to which formulation of
vaccine subjects had received prior to removal of the saline
formulated vaccine from the study. Neither the subjects nor
investigators were blinded once the saline formulation was
removed from the trial, because only one formulation was used
and because the dose-escalation design required that the safety of
the 20 mcg dose be evaluated prior to administration of the
50 mcg dose.
Statistical methods
Quantitative data were assessed for normal distribution and log-
transformation was performed where appropriate. Differences
among proportions were compared using Fisher’s exact tests,
differences between medians were compared using the Wilcoxon
Rank Sum test and Spearman’s Rank Correlation test was used to
assess association strengths. All tests were two sided. A P#0.05 was
taken to be statistically significant. R v2.2.0 [39] was used for
statistical analysis.
Results
Participant Flow and Recruitment
A total of 51 volunteers received at least one injection and 29
volunteers completed the study to receive all three injections of
ICC-1132 adjuvanted to Alhydrogel (Figure 2).
Baseline demographic data
The distribution of volunteers by gender and ethnicity was
similar statistically amongst all dose and formulation groups
(P=0.76). The median age of all trial participants was 25 years,
with a range of 18—45 years. There was a statistically significant
difference in participant age between the Baltimore (median age
26.5 [24 to 31]) and College Park (median age 21 [21 to 23])
cohorts (P=0.008).
Safety
The vaccine was well tolerated at the dose levels examined in
this study. No severe (grade 3) adverse events occurred, nor any
clinically significant laboratory abnormalities attributable to
Figure 2. Consort Flow Diagram. A total of 51 volunteers received at least one injection and 29 volunteers completed the study to receive all
three injections of ICC-1132 adjuvanted to Alhydrogel.
doi:10.1371/journal.pone.0001556.g002
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vaccination, in a volunteer who became pregnant within three
months of receiving the third 20 mcg injection. She delivered a
healthy infant at 40 weeks. No significant differences in reactoge-
nicity were noted between dose cohorts, between the first, second
and third vaccination, nor between Alhydrogel and saline vaccine
groups.
Local Reactogenicity. Of 125 total vaccinations admini-
stered to 51 volunteers, local adverse events were principally
limited to mild tenderness or pain at the injection site in 46
volunteers. In addition, four volunteers had local pruritus and one
volunteer each had an episode of induration and erythema
(Table 1). Most reactions were mild and lasted 1—3 days. There
were no severe reactions.
Systemic Reactogenicity. Headache and myalgia were the
most common manifestations of systemic reactogenicity, followed
by other elicited symptoms (Table 2). Symptoms were generally
mild and persisted 1—5 days. There were no severe or serious
reactions. Because no placebo group was included it is difficult to
ascribe causality to the vaccine. No delayed reactogenicity was
reported by the 28 volunteers who were contacted on day 336
follow-up (168 days after the third vaccination).
Immunogenicity
Humoral Immune Responses. Depending upon the
vaccine dose, 95—100% of volunteers developed specific
responses to the ICC-1132 vaccine immunogen (Table 3).
However, only 50—75% of the volunteers developed (T1B)4
malaria specific responses, while 29—63% developed IFA malaria
specific responses. There was no significant boosting of malaria
specific humoral immune responses [(T1B)4 and IFA] after the
third injection of ICC-1132 (Table 3). Less than a four-fold
boosting of anti-HBc titers occurred after the third injection in
both the 20 and 50 mcg cohorts. This increase in anti-HBc titer
was statistically significant in the 50 mcg cohort (P=0.02).
The anti-ICC-1132 and anti-HBc GMTs were significantly
higher in the 10 mcg cohort compared to the 20 and 50 mcg
cohorts after the second injection, although the percent responders
to the two antigens (90—100%) were nearly identical in the three
cohorts (Table 3). The 10 mcg cohort was not vaccinated a third
time. The anti-ICC-1132 and anti-HBc GMTs and percent
responders in the 20 and 50 mcg cohorts after each of three
injections were similar.
Malaria specific anti-(T1B)4 response was significantly higher in
the 10 mcg cohort compared to the 50 mcg cohort after the
second injection (P=0.019) (Table 3). Although the IFA GMT
and percent responders were higher in the 10 mcg as compared to
the 20 and 50 mcg cohorts, the differences were not statistically
significant. Overall, the malaria specific responses were low in
comparison to immunogen specific responses.
Anti-ICC-1132, anti-HBc and anti-(T1B)4 IgG1 and IgG3
subtypes, typical of TH1-type immune responses, developed
preferentially over IgG2 and IgG4 subtypes (P=3.33
25) without
affect of the adjuvant (P=0.21) (titer expressed in O.D.; data not
shown).
Two (volunteers 1 and 10) of the seven volunteers in the
10 mcg alum cohort (those with the most robust malaria specific
humoral responses) developed positive CSP reactions, which
demonstrates the presence of specific antibodies capable of cross-
linking surface CS protein on the viable sporozoite. Inhibition in
the TSNA using PfPb sporozoite invasion of HepG2 cells ranged
from a 54% inhibition (volunteer 3) to a 49% increase (volunteer
1) in 18S rRNA copies at 28 days post-vaccination two (10 mcg
cohort) or 28 days post-vaccination three (20 mcg cohort)
(Figure 3). TSNA data for the 50 mcg cohort is not available.
There was a correlation between IFA titer and CSP reactions,
though only two volunteers in the 10 mcg cohort had positive
CSP reactions (r=0 . 7 0 ,P=0.003). The two highest responders
by IFA and those with the positive CSP reactions, volunteers 1
and 10, demonstrated little to no inhibition by the TSNA
(Figure 3).
Cellular Immune Responses. Depending on vaccine dose,
65—75% of the volunteers’ demonstrated T cell proliferation in
response to ICC-1132 and 47—75% had proliferation to rCS.
The magnitude of responses to these two antigens was similar
(Table 4). Seven of 28 volunteers gave a T cell response to the
universal T cell epitope (T*)4, as measured by IL-2 bioassays
(Table 5). Only one volunteer had a consistent response to the
restricted CS repeat (T1B)4. Fifty-six days after the third injection
of the ICC-1132 vaccine no volunteer had significant cellular
immune responses in either the proliferation or the IL-2 bioassay
(data not shown). There was good correlation between the
proliferation assays and IL-2 bioassays (r=0.5—0.9, for
individual cohorts), though the P values for the 10 mcg cohort
correlations were .0.05.
Discussion
Interpretation
This P. falciparum CS-based malaria vaccine, a novel virus-like
particle, was safe and well tolerated. It elicited robust antibody
responses to the immunogen (ICC-1132) and to HBc, but the
malaria specific antibody responses were relatively weak. For
Table 1. Local Adverse Events by Episode in 125 Vaccinations
Local
Tenderness Pain Pruritus Induration Erythema
Grade 1* 68 53 4 1 1
Grade 2{ 1 9 000
Grade 3{ 0 0 000
Total 69 62 4 1 1
*Grade 1: Mild; no change in activity and/or no medication necessary
{Grade 2: Moderate; requires change in activity and/or medication
{Grade 3: Severe; bed rest required and/or medical intervention other than
medication alone (such as an outpatient visit in emergency department or
clinic, excluding hospitalization)
doi:10.1371/journal.pone.0001556.t001
Table 2. Systemic Adverse Events by Episode in 125
Vaccinations
Systemic
HA* Myalgia
Subjective
Fever{ Nausea Arthralgia Anorexia
Grade 1 14 12 4 3 4 4
G r a d e 2 6 313 00
G r a d e 3 0 000 00
Total 20 15 5 6 4 4
*HA=headache
{One episode of temperature to 37.8 C
doi:10.1371/journal.pone.0001556.t002
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to the ICC-1132 vaccine immunogen and to HBc, but only 50—
75% developed anti-CS repeat responses and 29—63% developed
IFA sporozoite responses (Table 3). The geometric mean titers by
IFA and rCS ELISA were suboptimal, arbitrarily defining an IFA
titer of 1500 as minimal adequate response for malaria challenge,
and only weak boosting was seen after the third vaccination. In
cellular responses, 8 of 28 (29%) and 7 of 28 (25%) responded to
rCS and the universal T cell epitope (T*)4 malarial antigens
respectively (Table 5). Because only a limited number of class II
genotypes can function as restriction elements for the CS repeat
epitope, it was not unexpected to find only 1 of 28 persons
consistently respond to the HLA-restricted (T1B)4 antigen
(Table 5). Although the cellular proliferation response to the
ICC-1132 and rCS antigens were similar, this candidate malaria
vaccine did not achieve our predefined criteria, a median IFA
response of .1:1500, to justify a malaria challenge.
Table 3. GMT of All Vaccinees (Percent Responders) Against Immunogen (ICC-1132), Hepatitis Core (HBc), Malaria Repeat Antigen
((T1B)4) and Whole Sporozoite (IFA)
Antigen ICC-1132* HBc* (T1B)4*I F A {
P o s t D o s e1 2 3123123123
10 mg 320 16255{,1 NA 63 4561",|| NA 67 269** NA NA 226 NA
(88) (100) - (33) (100) - (25) (75) - - (63) -
20 mg 123 905{ 3121 73 905" 2319 ,80 106 101 NA 80 66
(50) (100) (100) (50) (100) (100) (13) (50) (43) - (25) (29)
50 mg 88 10041 2661 49 577|| 2463 45 63** 138 NA 57 118
(48) (95) (94) (17) (90) (94) (8) (38) (53) - (25) (53)
*ELISA
{Indirect immunofluorescence assay
{P=0.008, between ICC-1132 10 and 20 mg cohorts post dose 2
1P=0.001, between ICC-1132 10 and 50 mg cohorts post dose 2
"P=0.03, between HBc 10 and 20 mg cohorts post dose 2
||P=0.007, between HBc 10 and 50 mg cohorts post dose 2
**P=0.019, between (T1B)4 10 and 50 mg cohorts post dose 2
Differences between 10, 20 and 50 mg cohort percent responders not statistically significant
Vaccination on days 0, 56 and 168
NA=Not available
doi:10.1371/journal.pone.0001556.t003
Figure 3. Comparison of Antibody Titer and Sporozoite
Neutralizing Activity for Select Volunteers. As measured by IFA
against whole sporozoite (gradient bars), (T1B)4 ELISA (hatched bars)
and transgenic sporozoite neutralization assay (TSNA) (percentages
above bars). For the TSNA, 94.5% inhibition was obtained using a
positive control monoclonal antibody specific for P. falciparum CS
repeats and 25% for negative control MAB specific for P. berghei CS
repeats. Volunteers with positive CSP assays, volunteers 1 and 10, are
indicated with a plus sign (+) in the x-axis.
doi:10.1371/journal.pone.0001556.g003
Table 4. TCL Proliferation Median dCPM (Percent
Responders) All Vaccinees Days 84 and 196
Cohort Day 0 Day 84 Day 196
ICC-1132 rCS ICC-1132 rCS ICC-1132 rCS
10 mg* 3033 4459 21744{ 23496{ NA NA
- - (75) (75) - -
20 mg{ 587 3484 15903 4736 10451 13772
- - (67) (75) (57) (29)
50 mg 310 462 36361 11948" 10035|| 11063||
- - (13) (29) (65) (47)
*Data from 4 volunteers
{Data from 7 volunteers
{Responses 14 days after the second dose of ICC-1132 (Day 70)
1Data from 8 volunteers
"Data from 14 volunteers
||Data from 17 volunteers
**Differences between 10, 20 and 50 mg cohorts dCPM & percent responders
not statistically significant
Vaccination on days 0, 56 and 168
NA=Not available
doi:10.1371/journal.pone.0001556.t004
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Intercohort Differences. Our most intriguing finding is the
difference between the 10 and 50 mcg cohorts in terms of humoral
immunogenicity of the vaccine. For all antigens evaluated, the
10 mcg cohort response was superior to that of the 50 mcg after
the second injection. Intercohort differences may have been an
effect of the manner in which antigen bound to the adjuvant in the
lower versus higher dose vaccines. Although unusual, it is not
without precedent that a lower immunogen dose would lead to a
more robust humoral response [40–42]. The vaccine lots differed
between the 10 mcg and the 20 and 50 mcg cohorts because of the
trial delay. The 10 mcg vaccine lot in our study was the same as
was used in the Cardiff study of 20 and 50 mcg cohorts [30] so it is
helpful to compare these results with our own. There remains a
statistically significant difference between our 10 mcg and the
Cardiff 20 and 50 mcg cohorts when comparing ICC-1132 GMT
at day 84 (GMT 989 and 1522 in the Cardiff 20 and 50 mcg
cohorts respectively) (P,0.035 in all cases), but there were no
statistically significant differences in the percent responders.
Hepatitis B Core Effects. Volunteers with preexisting anti-
HBc titers (two volunteers in the 10 alum and one volunteer in the
50 mcg cohort) demonstrated more robust humoral responses to
immunogen and HBc, with titers consistently higher than their
respective cohorts’ GMT. There was not a noticeably increased
response in these individuals against malaria-specific antigens.
This suggests that, in these previously anti-HBc positive
individuals, the more robust response against the immunogen
was specific for HBc epitopes. Indeed, the higher antibody titers
seen against both the immunogen and HBc in all the volunteers
could imply that the targeted epitopes in the immunogen are
shared HBc epitopes, rather than malaria epitopes. The
proliferation data shows that the cellular immune response is
targeting malaria-specific responses, as the median dCPM against
rCS and ICC-1132 are similar at day 196 (Table 4). As has been
demonstrated in other studies, the cellular immune response
against P. falciparum sporozoites is likely a critical component of
protection [7,43,44]. Analysis of cytokine and IFN ELISpot will be
reported in a separate paper (C. Othoro, manuscript in
preparation).
TH1 Type Response. Volunteers developed TH1-type
antibody, with anti-CS IgG1 and IgG3 subtypes developing
preferentially over IgG2 and IgG4, as found in previous study of
this vaccine [30]. This effect was independent of the adjuvant, as
similar predominance of IgG1 and IgG3 was note din the saline
group (data not shown), suggesting a TH1 inducing property of the
core particle [45]. The practical effect of a preferential TH1-type
antibody response would be production of gamma interferon, a
known inhibitor of hepatic stage intracellular parasites [43,46,47].
Functional Assays. The good correlation between (T1B)4
ELISA and IFA titers suggests that anti-repeat antibodies elicited
by the ICC-1132 vaccine recognize native CS on the sporozoite
(Figure 3). Two individuals with the highest IFA titers gave a
positive CSP reaction [30]. There was no correlation between
either IFA or CSP reaction and level of inhibition in the TSNA
using PfPb sporozoite invasion of HepG2 cells (Figure 3). It is
possible that our antibody titers and/or avidity were not sufficient
to lead to inhibition in the TSNA. In a previous study, antibodies
developed against a (T1B)4 MAP [27] vaccine demonstrated high
level inhibition of invasion of HepG2 cells in the TSNA [37],
however challenge studies were not carried out in that study and
correlation with protection in vivo remains unknown. In malaria
blood stage vaccines, functional assays based on transgenic
parasites expressing falciparum blood stage epitopes were more
predictive of protection, presumably because the ELISA does not
measure functional antibodies [48,49]. As yet there remains no
accurate correlate of protection for malaria sporozoite challenge
[15,18,50,51]. Previous studies have attempted to correlate
protection and inhibition of invasion of P. falciparum sporozoites
into hepatoma cells (ISI) assay [52–56]. Still others have suggested
the use of IFN-c ELISpot to measure T cell responses or
opsonizing anti-CS antibodies as correlates of protection [7,57].
Proper correlates of protection may well vary depending upon the
antigen/adjuvant combination tested.
Comparison to Other Studies of Same Immunogen. After
initiation of this present study in the USA, the vaccine was tested in
other, more limited studies in Europe, the results of which have
been published [30–32]. One study assessed immunogenicity of a
single injection of 5, 20 or 50 mcg of ICC-1132 formulated with
the more potent adjuvant, Seppic ISA 720, instead of Alhydrogel
[32]. A single dose of this 50 mcg ICC-1132/ISA 720 elicited
maximal GMT anti-repeat ELISA titers of 1050 (100%
seroconversion), higher than in the current study with maximal
anti-(T1B)4 GMT of 269 (75% seroconversion). In contrast, our
alum formulation elicited peak anti-HBc responses that were more
robust, exceeding 16000 GMT following booster immunization, as
compared to peak anti-HBc GMT of 830 elicited by a single
immunization with the ISA 720 formulation. In a second study of
the ISA 720 formulation, 9 of 11 volunteers receiving a single
50 mcg injection of ICC-1132/ISA 720 developed positive anti-
repeat antibody responses (GMT 370) but minimal T cell IFN
ELISpot responses [31]. Following challenge with P. falciparum
sporozoite, there was no appreciable effect of vaccination on
malaria infection, indicating that multiple immunization and/or
higher antibody titers or more robust cellular immune responses
are required for protection.
In summary, the candidate vaccine, ICC-1132, was safe and
well-tolerated at all dose levels examined in this trial. ICC-1132
was poorly immunogenic when adjuvanted with alum. The
immunogenicity of the candidate vaccine may be improved
through combination with a more potent adjuvant.
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Table 5. Fine Specificity of Malaria Specific Responses:
Median IL-2 CPM All Vaccinees (Number of Responders/
Number of Total, as measured by dCPM)
Cohort Antigen
rCS NF-54 (T*)4* (T1B)4
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50 mg{ 2831 (7/17) 147 (4/17) 55 (0/17)
Total Percent
Responders
29 (8/28) 25 (7/28) 4 (1/28)
*T universal epitope
{Responses 14 days after the second dose of ICC 1132 (Day 70)
{Responses 28 days after the third dose of ICC 1132 (Day 196)
Differences between cohorts not statistically significant
doi:10.1371/journal.pone.0001556.t005
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